Instrument Inactif

Autres langues Galapagos NV Euronext Bruxelles

Actions

GLPG

BE0003818359

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Galapagos : Galapagos presents encouraging new data for CD19 CAR T candidate GLPG5101 in non Hodgkin lymphoma at EHA 2024	17/06
Galapagos Plans to Present 'Encouraging' Results for GLPG5101 in Non-Hodgkin Lymphoma	14/06
Bemoedigende data Galapagos voor potentiele lymfeklierkankerbehandeling	14/06
Galapagos : presenteert bemoedigende nieuwe resultaten voor CD19 CAR T kandidaat GLPG5101 in non Hodgkin lymfoom op EHA 2024	14/06
Galapagos : presents encouraging new data for CD19 CAR T candidate GLPG5101 in non Hodgkin lymphoma at EHA 2024	14/06
Galapagos presenteert bemoedigende nieuwe resultaten voor CD19 CAR-T kandidaat GLPG5101 in non-Hodgkin lymfoom op EHA 2024	14/06
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024	14/06
Galapagos NV Presents Encouraging New Data for CD19 CAR-T Candidate GLPG5101 in Non-Hodgkin Lymphoma at EHA 2024	14/06
OPINIONI DEGLI ANALISTI DEL GIORNO : Tenaris, TIM, Stellantis, Leonardo, Enel, Davide Campari, Naturgy Energy, Pirelli, EQT...	07/06
OPINIONES DE LOS ANALISTAS DEL DÍA : Repsol, Inditex, Iberdrola, Cellnex, Rémy Cointreau, Mapfre, Naturgy Energy, HelloFresh, Sacyr...	07/06
Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment	31/05
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug	31/05
Galapagos : Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T cell therapy candidate, uza cel, in head & neck cancer and potential future so	31/05
Galapagos and Adaptimmune Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-Cell Therapy Candidate, uza-cel	30/05
Galapagos gaat samenwerken met Adaptimmune	30/05
Galapagos en Adaptimmune ondertekenen klinische samenwerkingsovereenkomst met optie om Adaptimmune's TCR T-celtherapiekandidaat, uza-cel, exclusief in te licentiëren voor hoofd- & halskanker en mogelijke toekomstige vaste tumoren indicaties	30/05
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications	30/05
OPINIONES DE LOS ANALISTAS DEL DÍA : Aedas, Endesa, Tubacex, Sabadell, BBVA, Unicaja, Repsol, Iberdrola, Nvidia, Intel, Richemont, Micron Technology...	20/05
LE OPINIONI DEGLI ANALISTI DEL GIORNO : Unicredit, Nvidia, Neste, Munich, Tenaris, Iberdrola, Ferrari, Iberdrola, Enel, Dell, Amplifon, Micron Technology...	20/05
Galapagos : Galapagos creates new subscription right plans	17/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Galapagos NV Euronext Bruxelles

Actions

GLPG

BE0003818359

Autres langues

Filtres